Notice Regarding the Completion of the Final Observation Period in the Phase 1 Clinical Trial of an Allergy Vaccine | FunPep Company Limited (4881) timely disclosure

Worth reading

32Immaterial

0–100. This measures how worthwhile something is to read, not how good or bad the company is.

Direction

Improvement

Direction inferred from the company’s description.

Scale

—

Displayed only when the document provides numerical figures.

Wording

Definitive

How definitive the wording is.

Completion of the Final Observation Period in the Phase 1 Clinical Trial of an Allergy Vaccine

Subject Entity

FunPep Company Limited (submitting company)

Target Locations / Products

Antibody-inducing peptide FPP004X; pollen exposure chamber

This disclosure05/07/2026

Accounting period in which recognized

Fiscal year ending December 2026

Impact on Earnings Forecast

No impact on the FunPep Group’s results for the fiscal year ending December 2026

Outlook

The Company plans to continue collecting and analyzing all data from the trial and disclose preliminary results in the third quarter of 2026 (July–September).

Planned follow-up disclosure

The Company plans to disclose preliminary results in the third quarter of 2026 (July–September).

Event that occurred
Item	Details
Event name	Completion of the Final Observation Period in the Phase 1 Clinical Trial of an Allergy Vaccine
Subject Entity	FunPep Company Limited (submitting company)
Target Locations / Products	Antibody-inducing peptide FPP004X; pollen exposure chamber
Accounting period in which recognized	Fiscal year ending December 2026
Impact on Earnings Forecast	No impact on the FunPep Group’s results for the fiscal year ending December 2026
Outlook	The Company plans to continue collecting and analyzing all data from the trial and disclose preliminary results in the third quarter of 2026 (July–September).
Planned follow-up disclosure	The Company plans to disclose preliminary results in the third quarter of 2026 (July–September).

Items this document does not state (18)

Date of occurrenceDate recognized / date notice receivedCauseAmount of Impact on Business PerformanceType of litigation or proceedingCourt or authorityPlaintiffDefendantDate of filing / date of actionClaim amount / surcharge amountAmount of receivables at risk of non-collection or delayed collectionSuspended operationsScheduled resumption dateInvestigation structureMeasures to prevent recurrenceDirectors' and officers' liabilityVoting rights ownership percentage before the changeVoting rights ownership percentage after the change

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

The final observation period for the last subject has ended, allowing the Company to proceed with the collection and analysis of all trial data.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.

Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.

Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.